Insight Molecular Diagnostics Q3 revenue beats, net loss narrows on cost cuts

By Reuters News


Overview

  • US diagnostics technology firm's Q3 revenue rose, beating analyst expectations

  • Net loss for Q3 narrowed from prior year as operating expenses declined

  • Company progressing with FDA review of GraftAssureDx and preparing for commercial launch


Outlook

  • Company expects to submit FDA response for GraftAssureDx before Jan 21, 2027 deadline

  • FDA review clock for GraftAssureDx to restart upon submission, with about half of 150-day review remaining

  • Company continues to target outgoing free cash flow of about $8 mln in Q4 2026


Result Drivers

  • LAB SERVICES REVENUE - Most Q3 revenue came from laboratory services performed at the company's CLIA-certified lab in Tennessee

  • GALACTIC STUDY ENROLLMENT - Company expects GraftAssureCore testing revenue to build as enrollment in the GALACTIC registry study grows

  • COST REDUCTION - Operating and R&D expenses declined sequentially as costs related to GraftAssureDx FDA submission wound down


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Revenue

Beat

$559,000

$244,200 (5 Analysts)

Q3 Net Loss

$3.58 mln

Q3 Pretax Loss

$3.58 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $8.00, about 273.8% above its November 13 closing price of $2.14


Reuters Recommended Reads

  • Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall

  • Nov 16 - Enanta Pharmaceuticals misses Q4 revenue estimates, posts wider net loss

  • Nov 16 - US FDA approves Roche's oral treatment for advanced breast cancer


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.